DaVita stock kpis
Want to see DVA full AI Analyst Report?
Revenue by Segment
DaVita reported revenue by segment of $3.58B in Q3 2026, up 0.7% from Q2 2026 and up 4.6% year over year. The highest value was $3.62B in Q4 2025.
Breaks down income across different business areas, showing where the company is earning the most and identifying growth or risk areas.
Dialysis remains the revenue engine but is growing steadily rather than explosively, while Ancillary Services has accelerated and is becoming a material diversification lever that will support margins over time; Eliminations are immaterial noise. Management’s call reinforces this: treatment volumes are picking up and IKC/International add modest OI, and cost savings from phosphate‑binder changes and expanded‑HD deployment should amplify ancillary economics. Near‑term risks—ACA mix pressure on revenue‑per‑treatment and elevated patient‑care cost growth—could temper margin upside despite the stronger ancillary trend.
DVA Revenue by Segment
| Period | Eliminations | Dialysis | Ancillary Services | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | -$24.12M | $3.05B | $551.77M | $3.58B |
| Q2 2026Jun 30, 2026 | -$14.00M | $3.01B | $557.00M | $3.56B |
| Q1 2026Mar 31, 2026 | -$24.00M | $2.94B | $498.00M | $3.42B |
| Q4 2025Dec 31, 2025 | -$23.00M | $3.08B | $567.00M | $3.62B |
| Q3 2025Sep 30, 2025 | -$14.70M | $2.98B | $454.89M | $3.42B |
| Q2 2025Jun 30, 2025 | -$20.00M | $2.91B | $486.00M | $3.38B |
| Q1 2025Mar 31, 2025 | -$14.00M | $2.82B | $415.00M | $3.22B |
| Q4 2024Dec 31, 2024 | -$23.00M | $2.89B | $430.00M | $3.29B |
| Q3 2024Sep 30, 2024 | -$19.00M | $2.91B | $376.00M | $3.26B |
| Q2 2024Jun 30, 2024 | -$17.00M | $2.84B | $362.00M | $3.19B |
| Q1 2024Mar 31, 2024 | -$27.00M | $2.76B | $342.00M | $3.07B |
| Q4 2023Dec 31, 2023 | -$24.00M | $2.81B | $360.00M | $3.15B |
| Q3 2023Sep 30, 2023 | -$27.00M | $2.79B | $363.00M | $3.12B |
| Q2 2023Jun 30, 2023 | -$22.00M | $2.73B | $292.00M | $3.00B |
| Q1 2023Mar 31, 2023 | -$23.00M | $2.61B | $284.00M | $2.87B |
| Q4 2022Dec 31, 2022 | -$27.00M | $2.66B | $285.00M | $2.92B |
| Q3 2022Sep 30, 2022 | -$23.00M | $2.70B | $268.00M | $2.95B |
| Q2 2022Jun 30, 2022 | -$19.00M | $2.66B | $283.00M | $2.93B |
| Q1 2022Mar 31, 2022 | -$22.00M | $2.58B | $265.00M | $2.82B |
| Q4 2021Dec 31, 2021 | -$21.00M | $2.70B | $263.00M | $2.94B |
| Q3 2021Sep 30, 2021 | -$22.00M | $2.70B | $262.00M | $2.94B |
| Q2 2021Jun 30, 2021 | -$21.00M | $2.68B | $261.00M | $2.92B |
| Q1 2021Mar 31, 2021 | -$31.00M | $2.59B | $261.00M | $2.82B |
| Q4 2020Dec 31, 2020 | -$45.00M | $2.67B | $276.00M | $2.90B |
| Q3 2020Sep 30, 2020 | -$41.00M | $2.69B | $271.00M | $2.92B |
| Q2 2020Jun 30, 2020 | -$40.00M | $2.67B | $245.00M | $2.88B |
| Q1 2020Mar 31, 2020 | -$36.00M | $2.62B | $261.00M | $2.84B |

